An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
Titel:
An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
Auteur:
Schöffski, P. Adkins, D. Blay, J.-Y. Gil, T. Elias, A.D. Rutkowski, P. Pennock, G.K. Youssoufian, H. Gelderblom, H. Willey, R. Grebennik, D.O.